Trials / Terminated
TerminatedNCT04945733
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
A Phase 2, Open-label Study of Amivantamab in Subjects With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected GC and EC population (Phase 2b).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amivantamab | Amivantamab will be administered intravenously. |
Timeline
- Start date
- 2021-08-30
- Primary completion
- 2023-07-03
- Completion
- 2023-07-03
- First posted
- 2021-06-30
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
10 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04945733. Inclusion in this directory is not an endorsement.